Press release from PR Newswire
Hologic Announces Launch of 6.25% Senior Notes Exchange Offer
Thursday, February 21, 2013
Hologic Announces Launch of 6.25% Senior Notes Exchange Offer16:58 EST Thursday, February 21, 2013BEDFORD, Mass., Feb. 21, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that it has commenced a registered exchange offer (the Exchange Offer) to exchange up to $1 billion aggregate principal amount of its 6.25% Senior Notes due 2020 which have been registered under the Securities Act of 1933, as amended (the Exchange Notes), for up to $1 billion of its outstanding 6.25% Senior Notes due 2020, which were issued on August 1, 2012 in a private placement (the Old Notes).The sole purpose of the Exchange Offer is to fulfill the Company's obligations pursuant to an exchange and registration rights agreement entered into by the Company in connection with the sale of the Old Notes. Under that agreement, the Company agreed to file with the Securities and Exchange Commission (the SEC) a registration statement relating to the Exchange Offer whereby Exchange Notes, containing substantially identical terms to the Old Notes, would be offered in exchange for Old Notes that are validly tendered by the holders of those notes.The Exchange Offer will expire at 5:00 p.m., Eastern Time, on March 22, 2013, unless extended (such time and date, as the same may be extended, the Expiration Date). Old Notes tendered pursuant to the Exchange Offer may be withdrawn at any time prior to the Expiration Date by following the procedures set forth in the prospectus pertaining to the Exchange Offer (the Exchange Offer Prospectus).The terms of the Exchange Offer are contained in the Exchange Offer Prospectus and related letter of transmittal. The Company has retained Wells Fargo Bank, National Association, to act as exchange agent for the Exchange Offer.Requests for assistance or for copies of the Exchange Offer Prospectus and the related letter of transmittal should be directed to:Wells Fargo Bank, N.A.Attention: Corporate Trust Operations, MAC N9303-121Sixth Street & Marquette AvenueMinneapolis, MN 55479Telephone: 800-344-5128Facsimile: 612-667-6282This press release is for informational purposes only and is neither an offer to exchange, nor a solicitation of an offer to sell, the Exchange Notes. The Exchange Offer is made solely pursuant to the Exchange Offer Prospectus, including any supplements thereto. The Exchange Offer is not being made to holders in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.About Hologic, Inc. Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.Forward-Looking StatementsThis press release contains forward-looking statements including those regarding the timing of the Exchange Offer. The word "will" and similar expressions are intended to identify the forward-looking statements. These forward-looking statements involve risks and uncertainties, many of which are beyond Hologic's control, and important factors could cause Hologic's actual results to differ materially from those in the forward-looking statements. For additional information on factors that could affect the forward-looking statements, see Hologic's risk factors, as they may be amended from time to time, set forth in Hologic's filings with the SEC, including its Registration Statement on Form S-4. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based, except as required by applicable law or regulation. Contacts: Deborah Gordon David CrossVice President, Investor Relations Vice President & Treasurer(781) 999-7716 (781) email@example.com firstname.lastname@example.org Al KildaniSenior Director, Investor Relations (858) email@example.com SOURCE Hologic, Inc.